LUDWIG ENTERPRISES, INC.

Ludwig Enterprises, Inc. is an early-stage genomic technology company that develops screening tests for inflammation-related chronic diseases, including cancers. Originally incorporated in 1988 and reorganized as a Nevada corporation in 2006, Ludwig pivoted in late 2021 to focus on genomic diagnostics, specifically mRNA-based testing. The company began actively pursuing its oncology diagnostics strategy in early 2022. Ludwig's technology utilizes a novel mRNA-based approach focused on dynamic gene expression, building on advances from the Human Genome Project. The company's first product candidate is the Revealia™ Breast test, which is anticipated to trial-launch in the second quarter of 2026. This platform integrates mRNA inflammatory biomarkers, proprietary machine-learning algorithms, and at-home cheek swab collection kits. Ludwig believes it is the first to employ a non-invasive cheek swab to collect sufficient mRNA samples for analysis. The approach aims to enable earlier detection of inflammation-driven disease and support personalized treatment decisions. The business model combines a business-to-business-to-consumer (B2B2C) strategy with partnerships through CLIA-certified laboratories. Ludwig intends to offer home collection kits directly to patients, supported by certified genetic counselors, and enable independent laboratories to provide the Revealia™ Breast test as a Laboratory Developed Test (LDT). The company relies on proprietary methods and intellectual property.